Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-29

Clinical Trial Update: Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing repeated administrations of NurOwn for amyotrophic lateral sclerosis (ALS) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NurOwn (MSC-NTF cells)

Snippet

Sponsor: Brainstorm-Cell Therapeutics | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Status: COMPLETED | Results posted: 2024-02-29